.svg)
Trevor Wear is a partner at the global law firm of Sidley Austin LLP. With more than 20 years of experience in healthcare administration and law, Trevor devotes much of his time partnering with life sciences companies to solve product launch, market access, strategic growth and compliance challenges in the U.S. and abroad.
2022's Inflation Reduction Act outlines three new prescription drug provisions. One of these provisions, the Medicare Drug Price Negotiation Program, sets an upper limit on the negotiated price for selected drugs, known as the maximum fair price.
The Drug Price Negotiation Program adds an entirely new level of operational complexity in a drug discount system already replete with systemic challenges. Though the Centers for Medicare & Medicaid Services has released initial guidance regarding the program, key players — especially drug manufacturers — have questions about the program's implementation.
We see the 340B Drug Pricing Program as a similarly significant and complicated federal drug discount program that can provide insights into how manufacturers may implement the Drug Price Negotiation Program.
By reading this report, you'll:
- Develop a valuable level of understanding of the Drug Price Negotiation Program
- Be able to identify the key similarities and differences between the Drug Price Negotiation Program and the 340B program
- Understand the Drug Price Negotiation Program's potential operational impacts
Download the whitepaper below to learn more.
